Latest News and Press Releases

New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing...

Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of...

MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,...

Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires...

Liquidia will report its first quarter 2025 financial results on Thursday, May 8, 2025.

Liquidia Corporation will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

Liquidia Corporation will provide an overview of the company’s business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.

The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder.

Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in 6MWD, cardiac effort and QoL.

Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the full year ended December 31, 2024.